Last reviewed 2026-04-20 · How we verify

PF-07867246 Influenza saRNA (pf-07867246-influenza-sarna)

Pfizer Inc. · Phase 1 active Quality 0/100

PF-07867246 Influenza saRNA (generic name: pf-07867246-influenza-sarna) is a drug developed by Pfizer Inc.. It is currently in Phase 1 development.

At a glance

Generic name	pf-07867246-influenza-sarna
Sponsor	Pfizer Inc.
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PF-07867246 Influenza saRNA CI brief — competitive landscape report
PF-07867246 Influenza saRNA updates RSS · CI watch RSS
Pfizer Inc. portfolio CI

Frequently asked questions about PF-07867246 Influenza saRNA

What is PF-07867246 Influenza saRNA?

PF-07867246 Influenza saRNA (pf-07867246-influenza-sarna) is a pharmaceutical drug developed by Pfizer Inc..

Who makes PF-07867246 Influenza saRNA?

PF-07867246 Influenza saRNA is developed by Pfizer Inc. (see full Pfizer Inc. pipeline at /company/pfizer).

What is the generic name of PF-07867246 Influenza saRNA?

pf-07867246-influenza-sarna is the generic (nonproprietary) name of PF-07867246 Influenza saRNA.

What development phase is PF-07867246 Influenza saRNA in?

PF-07867246 Influenza saRNA is in Phase 1.

Manufacturer: Pfizer Inc. — full pipeline
Compare: PF-07867246 Influenza saRNA vs similar drugs
Pricing: PF-07867246 Influenza saRNA cost, discount & access